0001140361-17-033562.txt : 20170829 0001140361-17-033562.hdr.sgml : 20170829 20170829170023 ACCESSION NUMBER: 0001140361-17-033562 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170825 FILED AS OF DATE: 20170829 DATE AS OF CHANGE: 20170829 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sanofi CENTRAL INDEX KEY: 0001121404 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: I0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 171058580 BUSINESS ADDRESS: STREET 1: 54 RUE LA BOETIE CITY: PARIS STATE: I0 ZIP: 75008 BUSINESS PHONE: 33153774400 MAIL ADDRESS: STREET 1: 54 RUE LA BOETIE CITY: PARIS STATE: I0 ZIP: 75008 FORMER NAME: FORMER CONFORMED NAME: SANOFI-AVENTIS DATE OF NAME CHANGE: 20040826 FORMER NAME: FORMER CONFORMED NAME: SANOFI SYNTHELABO SA DATE OF NAME CHANGE: 20010104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9143477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 4 1 form4.xml FORM 4 X0306 4 2017-08-25 0000872589 REGENERON PHARMACEUTICALS INC REGN 0001121404 Sanofi 54 RUE LA BOETIE PARIS I0 75008 FRANCE true Common Stock 2017-08-25 4 P 0 3684 479.1912 A 23811843 I See note Common Stock 2017-08-25 4 P 0 28586 479.9313 A 23840429 I See note Common Stock 2017-08-25 4 P 0 21360 480.7489 A 23861789 I See note Common Stock 2017-08-25 4 P 0 1302 481.6284 A 23863091 I See note Common Stock 2017-08-25 4 P 0 4485 482.8734 A 23867576 I See note Common Stock 2017-08-25 4 P 0 2000 484.21 A 23869576 I See note Common Stock 2017-08-25 4 P 0 5723 485.2798 A 23875299 I See note Common Stock 2017-08-25 4 P 0 2681 485.9939 A 23877980 I See note Common Stock 2017-08-25 4 P 0 2557 487.0108 A 23880537 I See note The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). Purchase prices range from $478.42 to $479.39 per share, inclusive. Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC ("Aventis"), formerly known as Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,080,985 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Purchase prices range from $479.43 to $480.39 per share, inclusive. Purchase prices range from $480.44 to $481.32 per share, inclusive. Purchase prices range from $481.47 to $482.09 per share, inclusive. Purchase prices range from $482.49 to $483.45 per share, inclusive. Purchase prices range from $483.70 to $484.63 per share, inclusive. Purchase prices range from $484.86 to $485.85 per share, inclusive. Purchase prices range from $485.86 to $486.79 per share, inclusive. Purchase prices range from $486.92 to $487.57 per share, inclusive. Exhibit 24 - Power of Attorney (incorporated herein by reference to Exhibit 24 to Form 4 filed by the Reporting Person with the SEC on February 3, 2016, with respect to Alnylam Pharmaceuticals, Inc.). /s/ Alexandra Roger Attorney-in-fact 2017-08-29